samedan logo
 
 
spacer
home > pmps > spring 2021 > foreword: respiratory drug delivery 2021
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Foreword: Respiratory Drug Delivery 2021

Inhalation Technology Supplement

Foreword: Respiratory Drug Delivery 2021

The adjective ‘disruptive’ frequently precedes new ideas and technology to highlight the significant advances they could enable, but it’s unlikely that any recent innovation has been as profoundly disruptive as SARS-CoV-2. Coronavirus changed the fabric of society within weeks, and the respiratory drug delivery community, along with everyone else, was compelled to adapt. Re-evaluating project priorities, working from home, rearranging laboratory and manufacturing workflows, and interacting with colleagues, patients, and clients online has been rapidly transformed around the globe. The pandemic caused disruption, but it simultaneously created opportunity for those of us concerned with pulmonary and nasal drug product development. Never have words like ‘lung disease’, ‘breathing’, and ‘aerosol droplets’ featured in so many news articles, and at no time in the past has there been such widespread appreciation of the scientists and clinicians who develop, produce, test, regulate, prescribe, and distribute medications and vaccines to treat COVID-19.

Many companies have accelerated programmes to investigate new drugs or repurpose existing ones in an urgent push to develop new treatments for COVID-19 and other lung diseases. Innovative technologies are being quickly developed so that nasal and pulmonary delivery of locally and systemically active drugs can be efficient and sustainable. Our historic focus was the treatment of disease by a drug product, but today the patient is the centre of attention. Can we help them use their inhaler or nasal spray correctly? Can we intervene before an exacerbation or life-threatening emergency? Can we leverage smartphones to improve inhaled therapies? Can we support quality of life? Can we make the products people want at reasonable cost to them and the planet? COVID-19 has provided renewed energy to achieve these priorities.

We will dive into these and other important topics at Respiratory Drug Delivery 2021, hoping to do our part to spur innovation, a goal we share with PMPS, who are graciously assisting in promoting our efforts and disseminating valuable information through their Inhalation Technology Supplement. At the same time, we are transforming the RDD® conference experience to meet the current realities of the pandemic.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
RDD 2021 Knowledge Spaces:

  • Pulmonary Progress: Respiratory Science Responds to SARS-CoV-2 and Lung Diseases
  • Propelling Inhalation Forward: Tools to Facilitate Low GWP Propellant Transition
  • Towards Greener Connectivity: Balancing the Needs of Patients and Our Planet
  • Perfecting Inhaled Particles: Advanced Inhaled Formulation Science
  • Front and Center – The Nose: Evaluating Regional Nasal Deposition
  • Live Events 4:00 - 6:15pm CET, 4-7 May 2021

More at www.rddonline.com/rdd2021
spacer
Richard Dalby
spacer
spacer
spacer
Carolyn Penot
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio

PHILADELPHIA – ASMS 2021 – (November 1, 2021) – Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography column.
More info >>

White Papers

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

RSSL

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement